LCK

The prevalence of soft tissue sarcoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of soft tissue sarcoma and the growing research and development activities to develop novel therapies to treat soft tissue sarcoma to drive the market. The companies developing the potential therapies in the last stage of development include Advenchen Laboratories, Philogen, Nanobiotix, and several others. LAS VEGAS, May 10, 2023 /PRNewswire/ -- DelveInsight's ' Soft Tissue Sarcoma Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline soft tissue sarcoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the soft tissue sarcoma pipeline domain. Key Takeaways from the Soft Tissue Sarcoma Pipeline Report DelveInsight's soft tissue sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for soft tissue sarcoma treatment. Key soft tissue sarcoma companies such as Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others are evaluating new soft tissue sarcoma drugs to improve the treatment landscape. Promising soft tissue sarcoma pipeline therapies in various stages of development include AL-3818, Onfekafusp alfa, Vigil, Tazemetostat, Aldoxorubicin, TAS-116, Selinexor, NBTXR3, APX005M, GPX-150, LTX-315, Lenvatinib, Chiauranib, Zalifrelimab, INCB081776, LN-145-S1, ABI-009, Tivozanib, LOXO-101, sEphB4-HSA, Sitravatinib, Envafolimab, Camrelizumab, Tigilanol Tiglate, Durvalumab, Tremelimumab, CFT8634, NOX66, Liposomal Annamycin, 609A, YH001, TAEST16001, CPI-613+Hydroxychloroquine, TBI-1301, Lurbinectedin, LYL132, and others. In October 2022, LIXTE Biotechnology Holdings, Inc. announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company's lead clinical compound, plus doxorubicin versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). In September 2022, Immutep Limited was pleased to announce it has signed a Material Transfer Agreement ("Agreement") with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, to enable an investigator-initiated open-label Phase II clinical trial. The trial will evaluate Immutep's lead product candidate, efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS). In September 2022, TRACON Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation for the development of envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in the tumor with the aim of sparing healthy tissue from exposure and improving the safety, tolerability, and efficacy of the drug. In May 2022, Immix Biopharma, Inc., announced positive interim study data showing that after one cycle of treatment, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. In this study, IMX-110 was compared against approved drugs used to treat STS. Trabectedin was dosed according to Meco et al., 2003 (trabectedin monotherapy treatment arm), and IMX-110 was administered at 2.0 mg/kg. In April 2022, Telix Pharmaceuticals Limited announced that it has entered into a license agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialize radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma (STS). Request a sample and discover the recent advances in soft tissue sarcoma drug treatment @ Soft Tissue Sarcoma Pipeline Report The soft tissue sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage soft tissue sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the soft tissue sarcoma clinical trial landscape. Soft Tissue Sarcoma Overview Soft-tissue sarcomas (STS) are rare neoplasms that can develop in supporting or connective tissue, such as muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They can also be found in the stomach and intestines (GIST), behind the abdomen (retroperitoneal sarcomas), and in the female reproductive system (gynecological sarcomas). Soft tissue sarcomas are classified based on the cell type involved, the nature of the malignancy, and the clinical course of the disease. The signs and soft tissue sarcoma symptoms differ greatly between patients depending on the type of soft tissue sarcoma. It is not associated with any obvious symptoms early in the course of the disease, but affected individuals may notice a slow-growing, painless mass in the affected area. Find out more about drugs for soft tissue sarcoma @ New Soft Tissue Sarcoma Drugs A snapshot of the Soft Tissue Sarcoma Pipeline Drugs mentioned in the report: Learn more about the emerging soft tissue sarcoma pipeline therapies @ Soft Tissue Sarcoma Clinical Trials Soft Tissue Sarcoma Therapeutics Assessment The soft tissue sarcoma pipeline report proffers an integral view of soft tissue sarcoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Soft Tissue Sarcoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Infusion, Intra-arterial, Intradermal, Intralesional, Intratumoral, Intravenous, Oral, Parenteral, Subcutaneous Therapeutics Assessment By Molecule Type: Antibody, Antibody-drug conjugate, Cell therapy, Gene therapy, Immunotherapy, Nanoparticle, Peptide, Recombinant fusion protein, Small molecule Therapeutics Assessment By Mechanism of Action: Fibroblast growth factor receptor antagonists, Platelet-derived growth factor beta receptor antagonists, Proto oncogene protein c-kit inhibitors, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists, Immunostimulants, Free radical stimulants, DNA intercalators, Type II DNA topoisomerase inhibitors, Cell membrane structure modulators, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Type 1 fibroblast growth factor receptor antagonists, Type 3 fibroblast growth factor receptor antagonists, Type 4 fibroblast growth factor receptor antagonists, Type-2 fibroblast growth factor receptor antagonists, Fms-like tyrosine kinase 3 inhibitors, Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Lyn protein-tyrosine kinase inhibitors, Src-Family kinase inhibitors Key Soft Tissue Sarcoma Companies: Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others. Key Soft Tissue Sarcoma Pipeline Therapies: AL-3818, Onfekafusp alfa, Vigil, Tazemetostat, Aldoxorubicin, TAS-116, Selinexor, NBTXR3, APX005M, GPX-150, LTX-315, Lenvatinib, Chiauranib, Zalifrelimab, INCB081776, LN-145-S1, ABI-009, Tivozanib, LOXO-101, sEphB4-HSA, Sitravatinib, Envafolimab, Camrelizumab, Tigilanol Tiglate, Durvalumab, Tremelimumab, CFT8634, NOX66, Liposomal Annamycin, 609A, YH001, TAEST16001, CPI-613+Hydroxychloroquine, TBI-1301, Lurbinectedin, LYL132, and others. Dive deep into rich insights for new drugs for soft tissue sarcoma treatment; visit @ Soft Tissue Sarcoma Medications Table of Contents For further information on the soft tissue sarcoma pipeline therapeutics, reach out @ Soft Tissue Sarcoma Drug Treatment Related Reports Soft Tissue Sarcoma Market Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key soft tissue sarcoma companies, including Gem Pharmaceuticals, Lytix Biopharma, Incyte Corporation, Daiichi Sankyo, NantPharma, Iovance Biotherapeutics, Agenus, Eli Lilly and Company, Adaptimmune, Aadi, AVEO Pharmaceuticals, Amgen, among others. Soft Tissue Sarcoma Epidemiology Forecast Soft Tissue Sarcoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the soft tissue sarcoma epidemiology trends. Clear Cell Sarcoma Pipeline Clear Cell Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key clear cell sarcoma companies, including Tesaro, NantPharma, Rafael Pharmaceuticals, Pfizer, among others. Ewing Sarcoma Pipeline Ewing Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Ewing sarcoma companies, including Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Scientists have performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response. Scientists at St. Jude Children's Research Hospital are reporting the most comprehensive study to date describing the variations in drug response across different genetic subtypes of acute lymphoblastic leukemia (ALL). The findings provide a blueprint for precision medicine to further individualize therapy. The study was published today in Nature Medicine. ALL, a cancer of lymphocytes (a type of white blood cells), is the most common childhood cancer. About 98% of children with ALL go into remission within weeks after starting treatment, and about 90% of those children will eventually be cured. Modern treatment for ALL is risk-adapted, meaning chemotherapy is tailored based on clinical features, leukemia genomics and the degree of minimal residual disease (MRD), which is the presence of microscopic levels of cancer cells that remain after initial treatment. Pharmacogenomics is the study of how genetic attributes affect drug response. St. Jude scientists have now comprehensively studied the pharmacogenomics of ALL by examining how the cancer cells respond to different therapeutics in the context of their cancer genomics. The results, from more than 800 patients, revealed wide variability across ALL, as well as distinct patterns of drug sensitivity by subtype. "Compared to traditional cancer genomics research, our pharmacogenomics work starts with defining the drug response phenotype of each patient, after which we look into genomics to search for the biological basis for the inter-patient variability in leukemia drug sensitivity," said corresponding author Jun J. Yang, Ph.D., St. Jude Department of Pharmacy and Pharmaceutical Sciences. "This approach sheds light on the therapeutic implications of specific genomic alterations, which may help clinicians alter care through a better understanding of how and why patients respond to treatment." "This work has yielded a wealth of new insights into the effectiveness of different medications used to treat childhood leukemia," said William Evans, PharmD, an emeritus faculty member and former St. Jude president and CEO, who co-led the study with Yang. "This work is the product of decades of collaborative research at St. Jude and across the pediatric cancer community. St. Jude may be the only place that can deploy technologies to generate discoveries at this scale across such a large number of children with cancer." The researchers found that ALL subtypes with the most favorable prognosis are closely tied to sensitivity to the chemotherapeutic drugs asparaginase and glucocorticoids. Surprisingly, some subtypes are similar in their genomics but have different patterns of drug sensitivities. The team also found that patients could be divided into distinct groups based on their drug sensitivity profiles which was associated with prognosis even after accounting for known risk factors. This highlights the importance of understanding these groups, ALL pharmacotypes, for survival outcomes. ALL from a functional perspective The researchers studied children with newly-diagnosed ALL, spanning different St. Jude flagship Total Therapy ALL clinical trials. The trials cover a period of over 20 years, generating a large and unique cohort of patient data. The scientists determined the sensitivity of leukemia cells to 18 different chemotherapy drugs in patients representing 23 molecular subtypes defined by leukemia genomics. The findings add a functional understanding to previous studies that identified high-risk or favorable subtypes. For example, ETV6-RUNX1 ALL has a favorable prognosis while BCR-ABL1-like ALL has a poor prognosis. These pharmacogenomics findings provided insight into why individuals with those subtypes had certain types of prognoses. Another potential application of these data is to discover biological pathways underlying drug sensitivity, which could pave the way for novel therapeutic development. For example, pharmacogenomics work by the Yang lab previously revealed that LCK activation underlies sensitivity to the drug dasatinib in T-ALL, making it an important target in some leukemias and spurring the development of several ongoing clinical trials to test the concept. For this study, the researchers analyzed hundreds of thousands of individual data-points. The work thus provides an important resource for the scientific community. "We hope our data will lead to more discoveries and new targets to drive a new generation of ALL trials in the near future," said first-author Shawn Lee, M.B.B.S., formerly of St. Jude and now of Khoo Teck Puat-National University Children's Medical Institute, National University Hospital Singapore. Results that matter for patients everywhere "ALL is actually a very heterogenous disease -- there are a lot of differences between genomic subtypes, such as presenting features and prognosis," Lee said. "Now, we have shown how drug sensitivity also varies between subtypes." The researchers would like to expand the findings with added population diversity. Such efforts to capture a more comprehensive picture of pediatric ALL pharmacogenomics around the globe would bring a biologically informed approach to future treatments. "This work is a big step in the right direction to individualize ALL therapy to spare children the side effects of drugs that will not work against their cancer, as well as to steer them to the novel therapies against which their cancer will likely respond," Yang said. "It is functional precision medicine, it's not just about the genetics and the targets but also about using the right drugs for the right patients." Authors and funding The study's other authors are Gary Rosner, Sidney Kimmel Comprehensive Cancer Center; and Wenjian Yang, Yoshihiro Gocho, August John, Lauren Rowland, Brandon Smart, Hannah Williams, Dylan Maxwell, Jeremy Hunt, Wentao Yang, Kristine Crews, Kathryn Roberts, Sima Jeha, Cheng Cheng, Seth Karol, Mary Relling, Hiroto Inaba, Charles Mullighan and Ching-Hon Pui of St. Jude. The study was supported by grants from the National Institutes of Health (GM115279, GM141947, CA26487, CA264610, CA021765), a Singapore NMRC Research Training Fellowship and ALSAC, the fundraising and awareness organization of St. Jude.

New York, May 17, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Singapore Data Center Market - Investment Analysis and Growth Opportunities 2021-2026" - According to the Government Technology Singapore, the government spent around USD 3.5 billion on ICT procurement in FY20, focusing on the development of new tech tools to respond to the COVID-19 pandemic, the development of citizen- and business-centric digital services, development of ICT systems on the cloud region, modernization of government ICT infrastructure; and application of data analytics, artificial intelligence (AI) and sensors in the public sector. With the internet penetration of 85% and the broadband speed pegged over 200 Mbps, Singapore has the highest average broadband speeds in Southeast Asia. The country accounted for over 40% of the data center area developed in Southeast Asia in 2020. The demand for data centers has also heightened the use of the existing data center capacity (MW) in the market, with colocation service providers witnessed a strong uptake for their data center spaces by existing customers. Cloud service providers and video conferencing service providers have contributed majorly toward colocation uptake archiving. The report considers the present scenario of the Singapore data center market and its market dynamics for the forecast period 2021?2026. It covers a detailed overview of several growth enablers, restraints, and trends in the market. The study includes the demand and supply aspects of the market. Key Highlights of The Report: • Over 30% of organizations have implemented cloud computing in Singapore due to the increased demand for data services from consumers and the growth in connected devices • The public cloud market spending crossed USD 2 billion in 2020, and is expected to grow significantly during the forecast period • Facebook invests in its first self-built facility in Singapore, which is likely to be operational by 2022 • The Singapore region accounted for over 40% of the data center area developed in Southeast Asia in 2020 • IoT-enabled devices have witnessed a high demand for monitoring and surveillance services with the outbreak of the COVID-19 pandemic, especially in the healthcare sector • The onset of the COVID-19 pandemic has increased the demand for data center services owing to the increase in internet-related services and the shift to remote working by organizations • The Electricity regulator Energy Market Authority (EMA) plans to import 100 MW of green energy from Malaysia by the end of 2021 to promote the consumption of green energy in Singapore. • AWS is building its first renewable power project in the region to generate over 60 MW of power. • Fuel cells can be installed in the facilities in Singapore to reduce the OPEX for operators. Singapore Data Center Market Insights • In 2020, the implementation of 5G and the increased usage of the internet increased the demand for cloud-based storage solutions among organizations in Singapore • Data centers adopt higher bandwidth switches at the aggregator layer, which includes 40/100 GbE switch ports • The demand for SDDs and NVMe SDDs is growing from cloud service providers and managed hosting providers in the country • The adoption of (DRUPS) Diesel Rotary Uninterruptible Power Supply systems, including flywheel UPS and diesel generators, is high among the service providers in Singapore • The implementation of the carbon tax in the region has prompted data center operators to opt for high-efficient gas generators to reduce carbon emissions. • Lithium-ion battery solutions with low CAPEX than traditional VRLA systems are observing high adoption in the facilities. Singapore Data Center Market Insights • In 2020, the implementation of 5G and the increased usage of the internet increased the demand for cloud-based storage solutions among organizations in Singapore. • Data centers adopt higher bandwidth switches at the aggregator layer, including 40/100 GbE switch ports. • The demand for SDDs and NVMe SDDs is growing from cloud service providers and managed to host providers in the country. • The adoption of (DRUPS) Diesel Rotary Uninterruptible Power Supply systems, including flywheel UPS and diesel generators, is high among the service providers in Singapore. • Implementing the carbon tax in the region has prompted data center operators to opt for high-efficient gas generators to reduce carbon emissions. • Lithium-ion battery solutions with low CAPEX than traditional VRLA systems are observing high adoption in the facilities. • The emergence of nickel-zinc batteries and the high adoption of 48V DC UPS systems will also provide a major boost to the Singapore data center market share. • Increased deployment of artificial intelligence and machine learning workloads will increase the application of liquid-immersion and direct-to-chip cooling systems. Singapore Data Center Market Vendor Landscape A host of IT infrastructure providers, construction contractors, support infrastructure providers, and investors constitute the Singapore data center market. Vendors are involved a flurry of infrastructure and construction activities. Arista Networks, Broadcom, Cisco Systems, Dell Technologies, Hewlett and Packard Enterprise (HPE) are some of the leading IT infrastructure providers. The market also witnessed the entry of new player Stratus DC Management, which has planned data center development in Singapore. IT Infrastructure Providers • Arista Networks • Broadcom • Cisco Systems • Dell Technologies • Hewlett Packard Enterprise (HPE) • Huawei Technologies • IBM • Inspur • Lenovo • MiTAC Holdings • NetApp • Quanta Cloud Technology • Wistron (Wiwynn) Construction Service Providers • Arup Group • AWP Architects • Aurecon Group • AECOM • Cundall • DSCO Group • Fortis Construction • Faithful+Gould • Gammon Construction • HDR (Hurley Palmer Flatt) • Kienta Engineering Construction • LSK Engineering • M+W Group (EXYTE) • NTT FACILITIES GROUP • PM Group • Sato Kogyo Support Infrastructure Providers • ABB • Bosch Security Systems (Robert Bosch) • Caterpillar • Cummins • Eaton • Fuji Electric • HITEC Power Protection • KOHLER-SDMO • Legrand • Mitsubishi Electric Corporation • Piller Power Systems • Rolls-Royce Power Systems • Rittal • Schneider Electric • Vertiv Group Data Center Investors • AirTrunk Operating • BDx (Big Data Exchange) • Digital Realty • Equinix • Facebook • Iron Mountain • NTT Global Data Centers • Keppel Data Centres • ST Telemedia Global Data Centres Report Coverage: This report on the Singapore Data Center market offers an elaborative analysis of the existing and upcoming facilities, datacenter investments in terms of IT, electrical, mechanical infrastructure, general construction, and geography. It discusses market sizing and estimation for different segments with respect to the investment in the facilities. The segmentation includes: Existing Vs Upcoming Data Centers • Existing Facilities in the region (Area and Power Capacity) o South o East o North • List of Upcoming Facilities in the region (Area and Power Capacity) Singapore Data Center Investment Coverage • Infrastructure Type o IT Infrastructure o Electrical Infrastructure o Mechanical Infrastructure • IT Infrastructure o Server o Storage o Network • Electrical Infrastructure o Uninterruptible Power Supply (UPS) o Generators o Transfer Switches and Switchgears o PDUs o Other Electrical Infrastructure • Mechanical Infrastructure o Cooling Systems o Rack Cabinets o Other Mechanical Infrastructure • General Construction o Building Development o Installation & Commissioning Services o Building Design o Physical Security o DCIM • Tier Segments o Tier I & Tier II o Tier III o Tier IV • Geography o Singapore Target Audience • Datacenter Real Estate Investment Trusts (REIT) • Datacenter Construction Contractors • Datacenter Infrastructure Providers • New Entrants • Consultants/Consultancies/Advisory Firms • Corporate and Governments Agencies Why Should You Buy This Research? • Market size available in the area, power capacity, investment, and colocation revenue. • An assessment of the Singapore data center investment in the market by colocation, hyperscale, and enterprise operators • Data center investments in terms of area (square feet) and power capacity (MW) across cities in the country • A detailed study of the existing Singapore data center market landscape, an in-depth industry analysis, and insightful predictions about the Singapore data center market size during the forecast period • Snapshot of existing and upcoming third-party facilities in Singapore o Facilities Covered (Existing): 38 o Facilities Identified (Upcoming): 4 o Coverage: 3 Regions o Existing vs Upcoming (Data Center Area) o Existing vs Upcoming (IT Load Capacity) • Data center colocation market in Singapore o Market Revenue & Forecast (2020-2026) o Retail Colocation Pricing o Wholesale Colocation PricingRead the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________